Carvolix: Strategic Growth in Medical Robotics and Financial Highlights

Carvolix, formerly known as Affluent Medical, has released its estimated financial results for 2025, highlighting a strategic transition towards medical robotics and innovative implants. Key developments include the acquisition of Caranx Medical and Artedrone, boosting their market portfolio with biomimetic implants and AI-driven micro-robots. The company secured a €10 million financing tranche to propel development, with plans to raise up to €30 million.

In 2025, Carvolix obtained FDA clearance for its TAVIPILOT software and began commercial deployment in the United States. Collaborations with Edwards Lifesciences reinforced its strategic positioning, especially for the Kalios™ mitral ring and the Epygon mitral valve, showcasing promising clinical results. Financially, Carvolix reported a net loss of €24.971 million for the year, reflecting substantial investments in innovation and expansion.